PMID-33320108 – Sensitivity and Specificity of Macimorelin Test for AGHD
Garcia JM, Biller BMK, Korbonits M, et al. Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocrine. 2021;72(1):117-133.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33320108 |
| DOI | 10.1007/s12020-020-02545-x |
| Year | 2021 |
| Journal | Endocrine |
| Study Type | Observational (Post-hoc Diagnostic Analysis) |
| Evidence Level | III |
| Sample | Pooled data from Phase 2 and Phase 3 studies |
| Peptide(s) Studied | Macimorelin |
Key Findings
- Post-hoc pooled analysis of sensitivity and specificity across Phase 2 and Phase 3 macimorelin studies
- Confirmed optimal GH cut-point of 2.8 ng/mL for diagnosing AGHD
- At 2.8 ng/mL cut-point: sensitivity 87%, specificity 96%, negative predictive value 92%
- Test performance was consistent across sex and age subgroups
- BMI may affect test performance — patients with BMI >30 had slightly lower peak GH values, potentially increasing false-positive rates
- Repeat testing showed 94% reproducibility, confirming high test-retest reliability
- Macimorelin test had comparable or superior diagnostic accuracy to GHRH+arginine and ITT
Study Design
Post-hoc analysis pooling data from Phase 2 (PMID: 23559086) and Phase 3 (PMID: 29860473) clinical studies. Re-analyzed sensitivity, specificity, and predictive values across different GH cut-points and patient subgroups (sex, age, BMI, number of pituitary hormone deficiencies). Examined test-retest reproducibility from repeated macimorelin administrations in a subset of patients.
Limitations
- Post-hoc pooled analysis — not a prospectively designed study
- ITT as reference standard has its own known limitations (subjective hypoglycemia criteria, poor reproducibility)
- BMI effect on test performance needs further prospective validation
- Limited data in patients with isolated GH deficiency (most subjects had multiple pituitary deficiencies)
- Potential for spectrum bias (patients referred for testing may differ from general population with suspected AGHD)
Clinical Relevance
This pooled analysis consolidates the diagnostic performance data for macimorelin, confirming its utility as the preferred GH stimulation test for adult GH deficiency. The high reproducibility (94%) is particularly notable because the ITT has notoriously poor reproducibility (~70-80%). For the Ageless Pep Academy, this study reinforces how GHS-R1a agonists (macimorelin, ipamorelin, MK-677, GHRP-6) reliably stimulate pituitary GH release, and that the magnitude of GH response to ghrelin receptor stimulation is a clinically validated biomarker for pituitary GH reserve. This principle underpins the rationale for using GH secretagogues therapeutically in age-related GH decline.
Related
#research #observational #macimorelin #evidence-level-III #gh-axis